Procedure Deep-Dive · November 15, 2026

Scleroderma and Cosmetic Surgery: The Small Mouth, Perioral Lines, Fat Grafting, Facial Red Spots, Morphea, Renal Crisis, and Anesthesia

Scleroderma changes the face in ways patients notice first and doctors often treat last: a mouth that will not open as wide, deep lines radiating from the lips, a pinched nose, and clusters of small red spots. Some of that can be softened, and fat grafting has real if modest evidence behind it. But systemic sclerosis also reaches the esophagus, the lungs, the heart, and the kidneys, and a routine dose of steroids for postoperative swelling can be dangerous in the wrong patient. Here is how to separate the two diseases that share the name, what actually helps the face, and what has to be checked before anyone goes to sleep.

By The Editorial Desk

18 min read

A woman in her late forties with short silver-streaked dark hair, wearing a chunky heather-gray knit cardigan, seated at a wooden table by a window with both hands wrapped around a gray ceramic mug, looking out the window with a slight smile

She is 49 and was diagnosed with limited cutaneous systemic sclerosis six years ago. It started, as it usually does, with her fingers turning white and then blue in the grocery store freezer aisle. A few years later the skin of her fingers tightened, and a rheumatologist found an antibody called anti-centromere and gave the condition its name. Her disease has been gentle by the standards of scleroderma. Her lungs are fine on the last scan, she takes a calcium channel blocker for the Raynaud's and a pill for reflux, and she works full time. What brings her to a cosmetic consultation is her face. Her lips have thinned and lines now fan out from them like spokes. She cannot open her mouth wide enough to bite into a sandwich, and her dentist has started using a child-sized mirror. Small red spots have appeared on her cheeks and lips. She wants to know whether filler, a laser, or "some kind of lift" could make her look like herself again.

Some of what she wants is reasonable, and a few of the options have better evidence than most cosmetic treatments enjoy. Some of it, particularly "a lift," misunderstands what the disease has done to her skin. And all of it sits on top of a condition that can quietly involve the esophagus, the lungs, the heart, and the kidneys, each of which matters to an anesthesiologist. This piece walks through the two different diseases called scleroderma, what the systemic form does to the face, what fat grafting, filler, and lasers can and cannot do, what has to be checked before surgery, and which medications, including some that cosmetic surgeons hand out routinely, deserve a second look.

Scleroderma and cosmetic surgery: two diseases share one name

The short answer: "scleroderma" covers two very different conditions, localized scleroderma (morphea), which affects the skin and sometimes the tissue beneath it but usually not the internal organs, and systemic sclerosis, which thickens the skin and can damage the blood vessels, gut, lungs, heart, and kidneys, and the difference determines almost everything about a cosmetic plan.

Systemic sclerosis is uncommon. Estimates for the United States usually land somewhere between 75,000 and 100,000 people, with women affected roughly four times as often as men and onset typically between 30 and 50. The disease has three features that run together: the immune system is activated, the small blood vessels are damaged and narrowed, and fibroblasts lay down too much collagen, which is what makes the skin thick and tight. The same scarring process can happen inside the body.

Rheumatologists divide systemic sclerosis into two main forms based on how far the skin thickening extends:

  • Limited cutaneous systemic sclerosis. Skin thickening stays on the fingers, hands, forearms below the elbows, lower legs, and face. This is the form once called CREST (calcinosis, Raynaud's, esophageal problems, sclerodactyly, telangiectasia). It tends to progress slowly, is often associated with the anti-centromere antibody, and carries a long-term risk of pulmonary arterial hypertension.
  • Diffuse cutaneous systemic sclerosis. Skin thickening also reaches the upper arms, thighs, chest, or abdomen, often quickly in the first few years. It is more often associated with anti-topoisomerase I (anti-Scl-70) antibodies, which travel with lung scarring, or anti-RNA polymerase III antibodies, which travel with rapid skin change and scleroderma renal crisis.

Raynaud's phenomenon is present in more than 95 percent of people with systemic sclerosis and is often the first sign by years. The longer story of how primary Raynaud's differs from the secondary kind that signals scleroderma is in our piece on Raynaud's phenomenon and cosmetic surgery, and anyone whose cold fingers began after about 30, come with fingertip sores, or come with puffy fingers should read it before booking anything elective.

Morphea is a different disease. It produces patches of hardened, shiny, sometimes discolored skin, usually on the trunk or limbs, and it rarely involves the internal organs. Two facial forms matter in cosmetic practice. Linear morphea of the forehead and scalp, called "en coup de sabre" because it looks like the mark of a sword blow, leaves a vertical groove with hair loss. Progressive hemifacial atrophy, also called Parry-Romberg syndrome, gradually wastes the fat, muscle, and sometimes bone on one side of the face. Both usually start in childhood or adolescence and often burn out after several years, leaving a contour defect that patients carry into adulthood. Our piece on facial lipoatrophy, HIV facial wasting, and Parry-Romberg covers the volume-replacement side of that problem in detail.

The practical consequence is simple. A patient who says "I have scleroderma" might have a burned-out forehead groove from age 12 and no internal disease at all, or might have active diffuse systemic sclerosis with lung scarring and kidneys at risk. Those patients need completely different conversations, and the surgeon who does not ask which one is in the room has not started the consultation.

The scleroderma face: small mouth, radial lines, thin lips, and red spots

The short answer: systemic sclerosis tightens and thins the facial skin, shrinks the mouth opening, thins the lips, deepens radial lines around the mouth, pinches the nose, and scatters small red telangiectasias across the face, and the treatments that help (fat grafting, cautious filler, vascular lasers, and stretching) work by adding volume, softening tissue, or removing vessels, not by lifting.

Facial involvement is common in both forms of systemic sclerosis. The face is one of the seventeen sites rheumatologists score on the modified Rodnan skin score, the standard exam for skin thickness in clinical trials, and a large share of patients have measurable thickening there. What patients notice, and what research on quality of life consistently shows they mind, comes down to a handful of changes:

  • Microstomia, the small mouth. Normal adult mouth opening, measured between the upper and lower front teeth, is typically around 40 to 50 millimeters. In systemic sclerosis it often drops into the 30s or lower. That affects eating, speaking, dental care, and, as discussed below, the airway during anesthesia. Researchers have built a questionnaire specifically for it, the Mouth Handicap in Systemic Sclerosis scale, which tells you something about how much it bothers people.
  • Radial perioral furrows. Deep vertical lines fan out from the lips. They look similar to the smoker's lines discussed in our piece on lip lines and perioral rejuvenation, but the cause is different: the skin is thick and contracted, not thin and creased from repeated pursing, so the same treatments do not behave the same way.
  • Thin lips and lost lip vermilion. The red part of the lip narrows as the skin around it tightens.
  • A pinched or beaked nose and a smooth, mask-like face. Fine wrinkles may actually disappear as the skin thickens, which some patients notice before anyone else does. The face can look younger in one way and stiffer in another.
  • Telangiectasias. Flat, matted, square-ish red spots on the face, lips, inside the mouth, and on the hands. They are especially common in the limited form, and they tend to multiply over time.
  • Pigment change. Some patients develop a "salt and pepper" pattern of light and dark spots, more visible in darker skin.

Here is what each tool can and cannot do.

Facelift and skin tightening. The problem in the scleroderma face is not too much skin. It is skin that is thick, bound down, and contracted. A deep plane facelift repositions loose tissue, and there is little loose tissue to reposition. Undermining thickened skin with a compromised blood supply also raises the risk of poor healing, and published experience with facelifts in active systemic sclerosis is close to nonexistent. Radiofrequency and ultrasound tightening devices are built to contract collagen, which is the last thing this skin needs more of. A surgeon who offers a lift as the answer to scleroderma facial changes has not thought hard about the disease.

Fat grafting. This is the treatment with the most published experience, and it gets its own section below. In short, fat adds volume to thin lips and perioral tissue and seems to soften the skin around it, with modest gains in mouth opening.

Hyaluronic acid filler. Small case series describe hyaluronic acid filler for perioral furrows and lip thinning in systemic sclerosis, with acceptable results and no signal of disease flares. The practical limits are physical: tight skin does not accept much volume, injection can be painful, and the tissue may blanch quickly because the small vessels are already narrowed. That last point matters because blanching is also the warning sign of a vascular occlusion, as explained in our piece on filler vascular occlusion risk, and an injector working in scleroderma skin needs to be fluent in telling the two apart. Reversible products are the sensible choice, for reasons covered in whether you can dissolve dermal filler. Biostimulatory fillers, which work by provoking collagen production, are a harder sell in a disease defined by too much collagen. The general distinction is laid out in biostimulatory fillers vs hyaluronic acid, and in scleroderma the theoretical argument against them is strong enough that most experts avoid them.

Vascular lasers for telangiectasias. Pulsed dye laser and intense pulsed light work well on scleroderma telangiectasias in small studies, often clearing them in a few sessions. The catch is that new ones keep forming, so this is maintenance rather than cure. The technical approach is the same as for other facial vessels, described in our piece on facial redness and broken capillaries. Bruising-level settings are usually unnecessary.

Ablative laser resurfacing. Fractional carbon dioxide laser has been tried for perioral tightness and microstomia in small reports, with some improvement in mouth opening, on the theory that controlled micro-injury remodels the stiff tissue. The evidence is thin and the healing risk in poorly perfused skin is real. The differences between laser types are covered in ablative vs non-ablative laser resurfacing. In scleroderma skin, a small test area and a conservative setting are the minimum.

Neurotoxin. A lip flip relies on relaxing a muscle so the lip rolls outward, and a stiff, tethered lip may not roll. Botulinum toxin has a separate, off-label role in scleroderma for severe Raynaud's in the hands, which belongs to the rheumatologist or hand surgeon, not the cosmetic visit.

Stretching. It is unglamorous, but mouth-opening exercises (stacked tongue depressors, finger stretching, and facial exercises done daily) have shown improvements of a few millimeters in small studies, comparable to some of the procedures above. Any cosmetic plan for microstomia that does not include them is leaving something on the table.

Fat grafting for scleroderma: what the studies actually show

The short answer: fat grafting to the face and hands in systemic sclerosis has been studied more than almost any other cosmetic intervention in a rheumatic disease, mostly in small uncontrolled series from European centers, and they consistently report better lip volume, softer perioral skin, and a few millimeters of extra mouth opening, while the one rigorous placebo-controlled trial of a fat-derived cell product in the hands did not beat placebo.

The idea is appealing. Fat carries not only volume but also a population of stromal and stem-like cells that secrete growth factors, and early researchers hoped those cells would reverse some of the fibrosis and improve blood flow. Whether that is what actually happens is still debated, but the clinical observations from the face are fairly consistent. Patients who have fat injected around the mouth, typically in small amounts with fine cannulas, tend to show:

  • fuller lips and softer, less furrowed perioral skin, on photographs and patient questionnaires
  • improvement in mouth opening, usually a few millimeters rather than a dramatic change
  • better scores on the Mouth Handicap in Systemic Sclerosis scale
  • no consistent signal that the procedure triggers a flare of the disease

The limitations are equally consistent. Most studies have a few dozen patients or fewer, no control group, and short follow-up. Fat survival in poorly perfused, scarred tissue is unpredictable, which is why repeat sessions are common. The basic biology of why some fat survives and some does not is in our piece on fat graft survival biology, and every factor that hurts survival (poor blood supply, tight recipient tissue, smoking) tends to be present in the scleroderma face. The general technique and expectations are covered in fat transfer to the face.

The hands are the other frequent target, mainly for pain, stiffness, and digital ulcers rather than appearance. Small series reported improvements in pain and hand function after fat grafting to the fingers. The most rigorous test so far was a French multicenter trial that injected a concentrated fat-derived cell preparation into the fingers and compared it with a placebo injection. Both groups improved, and the difference between them on the main measure of hand function was not significant at the primary time point. That does not prove fat grafting is useless, but it is a reminder that placebo effects and natural fluctuation are large in this disease and that uncontrolled series flatter whatever they test. For general cosmetic hand concerns, our piece on hand rejuvenation applies, with the caveat that anyone with scleroderma hands should have the work coordinated with their rheumatologist.

"The scleroderma face does not have too much skin. It has skin that is thick, tight, and short of blood supply. Anyone who answers that with a lift has misread the problem, and anyone who answers it with fat should promise millimeters, not miracles."

For morphea, the logic is different and the timing matters more. Fat grafting and filler are widely used to restore the forehead groove of en coup de sabre and the hollowing of Parry-Romberg syndrome, and results can be gratifying. The rule most surgeons follow is to wait until the disease has been inactive for a sustained period, often a year or more without new hardening, spreading, or color change, confirmed by the dermatologist or rheumatologist following it. Grafting into actively inflamed tissue risks poor take and a defect that keeps changing underneath the correction. Where the defect involves bone or is very deep, a dermal fat graft or implant may hold better than injected fat. Morphea patients on methotrexate can generally continue it around minor fat grafting, but that decision belongs to the prescribing doctor.

Before any anesthetic: the mouth, the esophagus, the lungs, the heart, and the kidneys

The short answer: systemic sclerosis can make the airway difficult, the stomach contents likely to reach the lungs, the lungs scarred, the pulmonary arteries narrowed, and the kidneys vulnerable, so any procedure beyond small amounts of local anesthetic in the office needs recent organ screening and an anesthesiologist who knows the diagnosis in advance.

The American College of Rheumatology and European scleroderma groups recommend regular screening for internal organ involvement, so many patients already have most of what a surgeon needs. The job is to collect it and read it with an operation in mind.

The airway. A small mouth, tight skin around the neck, and a stiff jaw can make it hard to insert a breathing tube or even place a mask. Anesthesiologists usually plan for this with video laryngoscopes or awake fiberoptic intubation. That is not exotic, but it requires preparation and the right equipment, which is one reason procedures needing general anesthesia belong in a hospital or accredited surgical facility, not an office suite. The broader logic is in our piece on choosing anesthesia and the operative plan. Thick forearm skin can also make intravenous access difficult, and cold operating rooms can trigger Raynaud's attacks, so warming matters.

The esophagus. Up to 90 percent of people with systemic sclerosis have esophageal involvement, mainly weak muscle contraction and reflux. Under anesthesia that raises the risk of stomach contents reaching the lungs. Patients should keep taking their reflux medication on the morning of surgery, and anesthesiologists may change their approach to induction. Some patients also have slowed stomach emptying, which matters for fasting instructions and, increasingly, for anyone also on a GLP-1 medication.

The lungs. Interstitial lung disease, scarring of the lung tissue, is a leading cause of death in systemic sclerosis and is detectable on high-resolution CT in a large share of patients. A recent CT and pulmonary function tests, including the diffusing capacity measurement that tends to fall early, tell the anesthesiologist how much reserve the lungs have.

The pulmonary arteries and heart. Pulmonary arterial hypertension, narrowing of the arteries in the lungs that strains the right side of the heart, affects roughly 8 to 12 percent of people with systemic sclerosis over time, more often in long-standing limited disease. It is one of the conditions in which anesthesia carries the most risk, because changes in blood pressure, oxygen, and fluid can push a struggling right ventricle into failure. An echocardiogram within the last year is standard screening, and anyone with known pulmonary hypertension should treat elective cosmetic surgery as a decision for their pulmonary hypertension specialist, not just their surgeon. The heart muscle and its electrical system can also be involved directly.

The kidneys. Scleroderma renal crisis is a sudden surge in blood pressure with rapidly failing kidneys. It is far less deadly than it was before ACE inhibitors became standard treatment, but it is still an emergency. It occurs mainly in diffuse disease, mostly in the first few years after onset, and especially in people with anti-RNA polymerase III antibodies. Its most clearly documented trigger is moderate to high doses of corticosteroids, which leads directly into the medication section below. Anyone with diffuse disease should know their antibody profile and baseline blood pressure and kidney function before surgery, and should check blood pressure at home in the weeks after. The general approach to elective surgery with reduced kidney function is in our piece on chronic kidney disease and dialysis before cosmetic surgery.

Wound healing. Thick skin with narrowed vessels heals slowly and breaks down more easily, especially on the hands, feet, and anywhere under tension. Incisions should be placed and closed with that in mind, and patients should know the signs of wound dehiscence. Smoking, already bad for any graft or flap, is close to disqualifying here.

Steroids, immunosuppressants, and vasodilators: the medication plan

The short answer: the single most important medication point is that corticosteroids, including the short courses many surgeons give for swelling, are linked to scleroderma renal crisis, so they should be avoided or kept low and discussed with the rheumatologist first, while immunosuppressants, antifibrotics, and vasodilators each need a deliberate continue, hold, or adjust decision.

Corticosteroids. Cosmetic surgeons commonly give dexamethasone during anesthesia to reduce nausea and swelling, and some send patients home with a tapering steroid pack after facial surgery. Our piece on steroids for swelling after plastic surgery explains why that practice is common. In systemic sclerosis, especially early diffuse disease, it deserves a second look. Observational studies have linked prednisone doses above roughly 15 milligrams a day to scleroderma renal crisis, and the major European scleroderma recommendations advise careful blood pressure and kidney monitoring in anyone receiving steroids. A single anesthetic dose of dexamethasone may be acceptable in a stable limited-disease patient, but that is a judgment for the anesthesiologist and rheumatologist together. A week-long steroid taper for swelling in someone with early diffuse disease and anti-RNA polymerase III antibodies is a different matter. Patients who take low-dose steroids long term have the opposite problem and may need their usual dose continued, as discussed in our piece on Addison's disease and stress-dose steroids.

Immunosuppressants. Mycophenolate is the most common background drug for skin and lung disease in systemic sclerosis, with methotrexate, cyclophosphamide, rituximab, and tocilizumab used in specific situations. The general framework for timing these around elective surgery, including which are usually held and for how long, is laid out in our piece on cosmetic surgery with autoimmune disease. The short version: the rheumatologist decides, the decision is written down, and an elective procedure is not a reason to let lung disease slip out of control.

Antifibrotics. Nintedanib, approved for lung scarring in systemic sclerosis, carries label warnings about bleeding and gastrointestinal perforation, and because it works partly by blocking blood vessel growth signals, surgeons reasonably worry about wound healing. It is commonly paused around surgery, with the timing set by the pulmonologist.

Vasodilators. Calcium channel blockers for Raynaud's, phosphodiesterase-5 inhibitors such as sildenafil or tadalafil, endothelin receptor antagonists such as bosentan, ambrisentan, or macitentan, and prostacyclin drugs for pulmonary hypertension or severe digital ulcers should generally not be stopped casually. Stopping pulmonary hypertension drugs abruptly can be dangerous. They do affect blood pressure under anesthesia, and the endothelin receptor antagonists cause serious birth defects and are dispensed under restricted programs with required pregnancy testing, which matters for any planning that involves future pregnancy. ACE inhibitors taken to protect the kidneys are usually continued in this disease, which is the reverse of the default advice for some other patients, and that decision should be explicit rather than accidental.

Pain medicines. Anti-inflammatory drugs such as ibuprofen and ketorolac strain the kidneys and the stomach, and both are already vulnerable in systemic sclerosis. Opioids slow a gut that may already move slowly. A pain plan built around acetaminophen, local anesthetic blocks, and limited opioids is usually the sensible starting point.

What about breast implants? Systemic sclerosis was at the center of the silicone breast implant litigation of the 1990s, when it was claimed that implants caused connective tissue diseases. Large epidemiological studies and the Institute of Medicine's 1999 review did not find a convincing link between implants and scleroderma, and that remains the scientific consensus, summarized in our piece on breast implant illness. That does not make breast surgery simple in someone with systemic sclerosis. The skin, the nipple circulation, and the anesthetic considerations above all still apply, and nipple vasospasm after breast surgery is more likely in someone with secondary Raynaud's. Someone who develops scleroderma after implants deserves a careful conversation, but removal is not a proven treatment for the disease.

Which procedures are reasonable? In a patient with stable limited disease, screened lungs and heart, and no pulmonary hypertension, small-volume facial fat grafting, reversible filler, vascular laser for telangiectasias, and modest body procedures are reasonable in principle with the precautions above. In early diffuse disease, the first few years when the skin is changing fast and the kidney risk is highest, elective surgery is generally a poor bet, and waiting until the disease has stabilized is the conservative choice most rheumatologists would endorse. In anyone with pulmonary arterial hypertension, the bar for elective general anesthesia is very high. For morphea without internal disease, the main question is whether the patch has been inactive long enough. Whatever the plan, a second consultation with a surgeon who has treated scleroderma patients before is worth the time, and if pigment change or scarring needs disguise rather than correction, the options in our piece on scar camouflage and medical tattooing are worth knowing about, with the same caution about blood supply.

The honest summary

Scleroderma and cosmetic surgery can coexist, but only after someone answers the first question correctly: is this morphea, a skin disease that often burns out and leaves a contour defect that fat grafting and filler can restore once it is quiet, or systemic sclerosis, a disease of thick skin, damaged blood vessels, and internal organs? In systemic sclerosis, the facial changes patients care about (a small mouth, thin lips, radial lines, red spots) respond modestly to fat grafting, cautiously placed reversible filler, vascular lasers, and daily stretching, and the evidence for fat is unusually real even if the gains are measured in millimeters. A facelift and collagen-tightening devices misread the problem. Before any procedure that needs more than local anesthetic, the patient should have recent lung, heart, and kidney screening, an anesthesiologist prepared for a difficult airway and reflux, and a medication plan that keeps the reflux, blood pressure, and pulmonary hypertension drugs going while treating steroids as a genuine risk rather than a routine swelling remedy. The right time is when the rheumatologist calls the disease stable and agrees in writing. The right surgeon is the one who asks which kind of scleroderma it is in the first five minutes. The wrong one hears "scleroderma" and reaches for a lift.